DGAP-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Strategic Company Decision/Joint Venture
​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176

10-Jan-2022 / 19:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

While shown to be highly effective in clinical trials, regulatory approvals previously limited Lutetium-177 based radiotherapeutics to rare cancer types such as neuroendocrine tumours. Recently, however, the FDA and other regulatory bodies extended approvals for Lutetium-177 based radiotherapeutics to prostate cancer, the second leading cause of cancer death. This has raised supply chain concerns among pharmaceutical producers, in particular about the scarce supply of Ytterbium-176.

'We are excited about the achievements of the team at Atom Mines and the potential of their isotope separation technology', commented Lutz Helmke, COO of EZR. 'They have closed an important gap in the supply chain for Lutetium-177 nca which will enable EZR to strengthen its position as a partner of choice for global radiopharmaceutical companies such as Novartis, Bayer, or Telix.'

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with approx. 900 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives

10-Jan-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de